IR Biosciences Holdings Inc. (IRBS) Research
IR BioSciences Holdings, Inc. is a U.S.-based, early-stage biotechnology firm. Through its subsidiary, ImmuneRegen BioSciences, Inc., it concentrates on researching and developing therapies for significant health challenges, including pulmonary fibrosis, influenza infections, and neutropenia caused by radiation. The company is also actively developing Homspera and its derivatives, Radilex and Viprovex. These compounds are designed to stimulate human stem cells, enhance immune system responses, offer anti-infective properties, serve as vaccine adjuvants, and promote wound healing. Founded in 1999, IR BioSciences Holdings, Inc. maintains its headquarters in Scottsdale, Arizona.
Market snapshot
- Symbol
- IRBS
- Price
- $0.00
- Day change
- 0.00%
- Market cap
- $128.1K
- P/E ratio
- -0.00x
- 52-week range
- 0.000001-0.00006
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- ZELDIS JEROME B — A-Award (35000 shares) on 2009-08-19
- Hariri Robert J — A-Award (200000 shares) on 2009-08-19
- Hariri Robert J — J-Other (100000 shares) on 2009-06-23
- Hariri Robert J — A-Award (100000 shares) on 2009-05-28
- Hariri Robert J — A-Award (1000000 shares) on 2007-08-01
Open IR Biosciences Holdings Inc. (IRBS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.